Home
overview

This Biomarkers Summit 2012 will provide a unique opportunity for debate and problem solving for key challenges facing the biomarkers fields as well as hearing from leading experts in this rapidly-evolving area. Now in its 5th year, this event will present attendees with the latest developments in the field through case-studies and insights from industry leaders in biomarker discovery and development as well as acting as the perfect forum for discussion.

With senior industry executives from Pfizer, AstraZeneca, GSK, Merck, Eli Lilly, Johnson & Johnson, Bayer and the FDA all presenting on their current work in a variety of different therapeutic areas; from oncology to immunology and respiratory to neurodegenerative diseases, this year’s conference is not to be missed!

The event will provide a complete picture of developments in the biomarkers field, focusing on biomarker development, discovery and validation as well as technological and regulatory updates and will be the ideal opportunity for problem-solving discussion and idea-sharing debate.

 Feedback on last year's event included:

“It gave me a 360° overview of the research in this field”

“A very good networking opportunity and information gathering”

“Thank you very much for a great meeting”

     

 

 

• Evaluate translational biomarkers in immune modulation from pre-clinical to humans

• Demonstrate target activity modulation based on pharmacodynamic markers

• Advances in In-Vivo oxygen amperometry as a surrogate for fMRI in behaving rodents

• Consider EEG as a target engagment biomarkers

 Develop understanding of imaging modalities in preclinical biomedical imaging

• Discuss the benefits of biomarkers as the perfect pathogenic tools 

• Understand theranostic development in oncology 

Our key industry speaker line up includes:

Hans Winkler, Senior Director and Global Head, Oncology Biomarkers, Johnson & Johnson
Arndt Schmitz,
Founding Scientist, Bayer Schering Pharma
Weida Tong,
Director of Center for Bioinformatics, NCTRT/FDA
Terry Walker,
Director, Translational Immunology, Pfizer
Bjoern Riefke,
Head of Metabolic Profiling and Clinical Pathology, Bayer Schering Pharma
Gary Gilmour,
Senior Research Scientist, Eli Lilly
Hugh Salter, Laboratory Head, Translational Sciences, AstraZeneca
Sabin Carme, Translational Imaging Scientist, GSK
Johan Luthman,
Senior Program Leader, Early Development, Neuroscience & Opthamology R & D, Merck
Mark Fidock,
Group Director & Global Head Biomarkers and Translational Sciences, Huntingdon Life Sciences (Formerly of Pfizer)
Andrew Payne,
Senior Group Leader Cellular Pharmacology, UCB
Darren Hodgson,
Biomics Advisor, AstraZeneca
Daniel Bradley,
Head of Biomedical Imaging Group, Millennium Pharmaceuticals
Richard May, Head of Biology, Respiratory, Medimmune
Meagan Myers,
Staff Fellow, U.S. FDA
Jennifer Larsen,
Translational Medicine Scientist, Lundbeck

Some example job titles for professionals who could benefit from attending this conference:

 

  • Biomarker Discovery and Validation
  • Biobanking 
  • Research and Development                             
  • Neurology/Neuroscience
  • Oncology
  • Proteomics/Genomics/Matabolomics
  • Exploratory Biomarkers
  • Respiratory
  • Toxicology
  • Clinical Pathology
  • Toxicology/Toxicogenomics
                          

 

  • Molecular Biology
  • Medical Directors 
  • Imaging and Diagnostics
  • Translational Medicine
  • Biostatistics and Modelling
  • Cell Biology
  • Drug and Safety Assessment
  • Experimental Medicine
  • Early Clinical Development
  • Pharmacokinetics/Pharmacodynamics
  • Genomics/Bioinformatics/Neuroinformatics

 

Attendees from last years event came from across the world...  

...and from a broad range of senior pharmaceutical positions. Join the wide range of high level delegates again at our event in 2012...

                               

     In our 2011 conference, attendees came from all over Europe, USA and Asia and included senior executives from:

  • Pfizer                                                                      
  • GlaxoSmithKline
  • AstraZeneca
  • Abbott
  • Johnson & Johnson
  • Lundbeck
  • Roche Pharmaceuticals
  • Merck & Co
  • BGI
  • NHS
  • University of Cambridge
  • Cell Signalling Technology
  • Selventa
  • Exiqon
  • Millipore
  • University of Essex
  • Rules Based Medicine
 
  • Eli Lilly
  • Novartis
  • MedImmune
  • Amgen
  • Grunenthal
  • Astellas
  • European Commision
  • Cancer Research Technology
  • Innaxon
  • King's College London
  • Quintiles Ltd
  • Neurosearch
  • University of Florida
  • Caprotec Bioanalytics
  • London Technology Network
  • University of East Anglia
  • Institute of Food Research

 

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Mark Fidock

Mark Fidock, Group Director & Global Head Biomarkers and Translational Sciences, Huntingdon Life Sciences (Formely of Pfizer)

9:10 Translational biomarkers

Mark Fidock

Mark Fidock, Group Director & Global Head Biomarkers and Translational Sciences, Huntingdon Life Sciences (Formely of Pfizer)

• Development of techniques to successfully identify biomarkers linked to the therapeutic mechanism
• Biomarkers enabling early predictions using PK/PD modelling
• Utilization of biomarkers in early clinical drug development decision making
• Case study utilization of biomarkers in immune modulation from pre-clinical species to man

9:50 Characterisation of biomarkers for novel inhibitors of PI3K for use in autoimmune disease

Andrew Payne

Andrew Payne, Senior Group Leader, UCB Pharma

• Challenges associated with biomarker development in autoimmune disease
• Discovery and characterization of biomarkers of PI3K signalling in immune cells
• Application of biomarkers in pre-clinical studies

10:30 Morning Coffee

10:50 Translating miRNA discovery in biofluids into robust clinical biomarkers

Adam Baker

Adam Baker, Director of Diagnostic Product Development, Exiqon

• Development of a LNA™-based microRNA qPCR system to detect microRNAs in challenging clinical material such as body fluids
• Considerations in transforming biomarker discovery results into assay development.
• Case study on microRNA biomarkers enabling early detection of colorectal cancer

11:30 Implementation and value of biomarkers in early development

Hans Winkler

Hans Winkler, Senior Director Translational Research, Oncology, J & JPRD

• Proof of principle by demonstrating target activity modulation, based on pharmacodynamic markers based on sample and assay quality
• Identification of sensitive tumours using predicitive biomarkers 
• Discussing target related, sensitivity "signatures", application for proof of concept (disease modulation) and companion diagnostic issues

12:10 Immune response profiling and monitoring for active immunotherapeutics

12:50 Networking Lunch

14:10 Biomarker discovery for peanut allergy diagnostic, monitorisation and treatment end point definition

Victor Turcanu

Victor Turcanu, Lecturer in Paediatric Allergy, King's College London

• Recent developments of novel therapies for peanut valuating diagnostic biomarkers for food allergy led to a need to identify biomarkers to monitor these treatments and define surrogate end-points, whilst increasing safety and entailing lower costs
•  Novel biomarker panels have recently been proposed for allergy. We used quantitative real-time PCR and microarrays to identify such biomarkers, for example expression of specific cytokines in peanut stimulated blood cells. These biomarkers will be further validated in the large clinical trials that we are currently carrying out.

14:50 In vivo oxygen amperometry - a potential surrogate for fMRI in behaving rodents

Gary Gilmour

Gary Gilmour, Senior Research Scientist, Lilly Research Centre

• Overview of amperomtery, and how it compares to fMRI
• Advances in in vivo oxygen amperomtery
• Its uses and benefits in neuropsychiatric diseases
• Success stories and common obstacles
 

15:30 Afternoon Tea

15:50 Integrative biomarkers in neurodegenerative disease

Hugh Salter

Hugh Salter, Laboratory Head, AstraZeneca

Biomarker strategies for diagnosis & disease progression
Case studies from MS & AD
Integrative analysis as a key future tool

16:30 Biological Fingerprints for Depression – working towards predicting treatment response

Jennifer Larsen

Jennifer Larsen, Translational Medicine Scientist, Lundbeck H A / S

Using gene expression profiling to identify differences between individuals with MDD and healthy controls
Using gene expression profiling to identify subpopulations                                                                                          
Linking the biology to the disease

17:10 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Magnus Nord

Magnus Nord, Associate Professor, Safety Science Physician, AstraZeneca

9:10 Aiding Biomarker Development Through Effective Industry-Academia Partnerships

William Gallagher

William Gallagher, Associate Professor of Cancer Biology, University College Dublin

- Development of Tissue-Based Biomarkers
- Role of Industry-Academic Partnerships
- Case Studies from European Framework Programmes

9:50 A new VISIONS for VXDS - a perspective view of the FDA's pharmacogenomics data submission

Weida Tong

Weida Tong, Director of Center for Bioinformatics, NCTR/FDA

Regulatory update from the FDA
The future of VXDS
How best to prepare for the submission process

10:30 Morning Coffee

10:50 Importance of patient stratification in delivering new therapeutics

Richard May

Richard May, Head of Biology - Respiratory, MedImmune

• A one size all approach doesn’t yield ideal results:
     o Lessons from mepolizumab
• Asthma is a heterogeneous disease
     o SARP, Leicester, Woodruff/UCSF data
• Stratification approaches yield results and is the likely future paradigm
     o Mepolizumab, AMG-317, aerovant, lebrikizumab

 

11:30 Development and Application of Clinical Safety Biomarkers with a focus on Imaging biomarkers

Magnus Nord

Magnus Nord, Associate Professor, Safety Science Physician, AstraZeneca

• Clinical safety biomarkers – definitions and key principles
• Development, validation and qualification of safety biomarkers for clinical use
• Utility of imaging methods for clinical safety biomarker applications
• Examples of imaging as clinical safety biomarkers in drug development

12:10 Networking Lunch

13:30 miRNA as lung disease biomarkers

Sterghios Moschos

Sterghios Moschos, Reader in Industrial Biotechnology, University of Westminster

• Detecting cancer in blood plasma using miRNA based signatures
• Explaining why miRNAs are successful biomarkers
• Discussing compatibility with standard clinical procedures

 

14:10 Quantification of hotspot oncomutation: Implications for personalized cancer treatment

Meagan Myers

Meagan Myers, Staff Fellow, National Center for Toxicological Research

• Overview of the sensitive and quantitative method- Allele-Specific Competitive Blocker PCR.
• Data on the frequencies of MAPK-associated hotspot oncomutations in normal human tissues and tumor samples
• Are KRAS mutant subpopulations undermining the patient stratification necessary for personalized medicine?
 

14:50 Discovery and validation of biomarkers in nephrotoxicity

Bjoern Riefke

Bjoern Riefke, Head of Metabolic Profiling and Clinical Pathology, Bayer Schering Pharma AG

• Early prediction of nephrotoxicity
• Discussing why biomarkers are the perfect pathogenic tools for this process
• Integration of present applications, and emerging applications, according to the business leaders

15:30 Chairman’s Closing Remarks and Close of Day Two

15:40 Afternoon Tea

+

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.